Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Eligibility for faricimab in a real-world diabetic macular oedema population: a cross-sectional study
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Oftalmiatrik.ORCID-id: 0000-0002-2147-602x
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk och translationell biologi.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin.ORCID-id: 0000-0002-6785-2895
2025 (Engelska)Ingår i: BMJ Open, E-ISSN 2044-6055, Vol. 15, nr 2, artikel-id e089801Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Purpose: To investigate the eligibility for faricimab in a real-world diabetic macular oedema (DMO) population to the YOSEMITE and RHINE trials, and to compare the eligible DMO populations to the trial populations.

Design, settings and participants: This retrospective cross-sectional analysis used data from the Swedish Macula Registry (SMR) between 1 January 2019 and 31 August 2023. Eligibility criteria mirrored the main criteria of the YOSEMITE and RHINE trials: (1) DMO diagnosis, (2) treatment-naïve, (3) 18 years or older, (4) central retinal thickness (CRT) 325 µm or higher and (5) best-corrected visual acuity (BCVA) ranging from 25 to 73 letters. Individuals with registered proliferative diabetic retinopathy (DR) at the start of treatment were excluded. A secondary selection of eligible individuals was conducted using the same criteria, except for BCVA, which ranged from 25 to 77 letters according to national guidelines (treatment practice).

Main outcome measures: Characteristics at the initial visit of the two eligible SMR populations were compared with baseline data from the clinical trials, respectively.

Results: In total, 3777 individuals with DMO were selected from SMR. Of these, 2357 (62.4%) individuals were treatment-naïve, all were 18 years or older, 1928 (51.0%) exhibited CRT≥325 µm, 1175 (31.1%) had 25-73 letters based on phase III studies, while 1528 (40.5%) had 25-77 letters according to treatment practice. After excluding individuals with registered proliferative DR 1171 (31.0%) individuals in the SMR met all criteria based on phase III studies, while 1522 (40.3%) individuals fulfilled the criteria according to treatment practice. The SMR and treatment practice populations were older (YOSEMITE 67.5±11.6 vs 62.8±10.0 years, p<0.001 and RHINE 67.5±11.6 vs 61.6±10.1 years, p<0.001) than those in the phase III studies and had lower CRT (YOSEMITE 446±96 vs 486±131 µm, p<0.001 and RHINE 446±96 vs 471±127 µm, p=0.001).

Conclusion: Approximately 30% of DMO patients in the SMR met the main trial criteria from YOSEMITE and RHINE, while around 40% met the criteria based on treatment practice. The SMR and treatment practice cohorts were older and had less severe DMO than the trial cohorts. Further research into the safety profile of faricimab in clinical settings is necessary, along with the consideration of additional eligibility criteria when implementing faricimab in ophthalmology practice.

Ort, förlag, år, upplaga, sidor
BMJ Publishing Group Ltd, 2025. Vol. 15, nr 2, artikel-id e089801
Nyckelord [en]
Cross-Sectional Studies, Diabetic retinopathy, Drug Therapy, OPHTHALMOLOGY, REGISTRIES
Nationell ämneskategori
Endokrinologi och diabetes Oftalmologi
Identifikatorer
URN: urn:nbn:se:umu:diva-235649DOI: 10.1136/bmjopen-2024-089801ISI: 001414619900001PubMedID: 39909510Scopus ID: 2-s2.0-85217090959OAI: oai:DiVA.org:umu-235649DiVA, id: diva2:1940056
Tillgänglig från: 2025-02-25 Skapad: 2025-02-25 Senast uppdaterad: 2025-02-25Bibliografiskt granskad

Open Access i DiVA

fulltext(246 kB)29 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 246 kBChecksumma SHA-512
789228ea692c32b458655dae7dc39217eab79303c43e515af7f30fae6d96d12373e5a68db7c7341ad6b035f30c714c005a34086a91a2d5a21832d7c15034aa3d
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Westborg, IngerNorberg, Helena

Sök vidare i DiVA

Av författaren/redaktören
Westborg, IngerNorberg, Helena
Av organisationen
OftalmiatrikInstitutionen för medicinsk och translationell biologiInstitutionen för folkhälsa och klinisk medicin
I samma tidskrift
BMJ Open
Endokrinologi och diabetesOftalmologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 29 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 259 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf